rVSV-ZEBOV 全名重組水泡性口炎病毒-薩伊伊波拉病毒 （Recombinant vesicular stomatitis virus–Zaire Ebola virus），又稱伊波拉病毒活毒疫苗 （Ebola Zaire vaccine live），商品名 Ervebo ，是抗薩伊伊波拉病毒 、避免人類伊波拉出血熱 的疫苗 [ 3] [ 4] [ 5] [ 6] 環形免疫接種 [ 7] [ 8] [ 9] 重組 病毒載體疫苗 [ 10] 醣蛋白 的水泡性口炎病毒 免疫反應 [ 3] [ 11]
此疫苗最初由加拿大國家微生物實驗室 研究團隊開發，於2003年申請專利[ 12] [ 13] 默克藥廠 [ 14] [ 4] [ 15] [ 11] [ 16] 2018年剛果赤道省伊波拉出血熱爆發 中此疫苗首次被用於控制伊波拉疫情[ 17] 該國基伍地區的嚴重疫情 中被大量使用[ 9]
約有半數此疫苗的施打者出現輕度至中度的副作用，包括頭痛、疲倦、肌肉痠痛等[ 7]
^ Monath TP, Fast PE, Modjarrad K, et al. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment . Vaccine: X. April 2019, 1 . 100009. PMC 6668225 PMID 31384731 doi:10.1016/j.jvacx.2019.100009 ^ Ebola Vaccine: Information about Ervebo . Centers for Disease Control and Prevention (CDC). February 26, 2020 [April 16, 2021] . （原始內容存檔 於2021-04-16）. ^ 3.0 3.1 3.2 Ervebo (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection (PDF) . Merck Sharp & Dohme. [2022-11-06 ] . （原始內容存檔 於2020-03-29）. ^ 4.0 4.1 4.2 Ervebo EPAR . European Medicines Agency (EMA). October 16, 2019 [March 29, 2020] . （原始內容存檔 於2021-03-08）. ^ Trad MA, Naughton W, Yeung A, et al. Ebola virus disease: An update on current prevention and management strategies . Journal of Clinical Virology. January 2017, 86 : 5–13. PMID 27893999 doi:10.1016/j.jcv.2016.11.005 hdl:10144/618818 ^ Pavot V. Ebola virus vaccines: Where do we stand?. Clinical Immunology. December 2016, 173 : 44–49. PMID 27910805 doi:10.1016/j.clim.2016.10.016 ^ 7.0 7.1 Medaglini, D; Siegrist, CA. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine. . Current Opinion in Virology. April 2017, 23 : 88–94. PMID 28460340 doi:10.1016/j.coviro.2017.03.008 ^ Mole, Beth. As Ebola outbreak rages, vaccine is 97.5% effective, protecting over 90K people . Ars Technica. April 16, 2019 [April 17, 2019] . （原始內容存檔 於2021-02-19）. ^ 9.0 9.1 Ebola Ring Vaccination Results April 12, 2019 . World Health Organization (WHO) (報告). April 12, 2019 [April 17, 2019] . （原始內容存檔 於2022-11-06）. ^ Marzi, Andrea; et al. Vesicular Stomatitis Virus–Based Ebola Vaccines With Improved Cross-Protective Efficacy . Journal of Infectious Diseases. November 2011, 204 (suppl 3): S1066–S1074. PMC 3203393 PMID 21987743 doi:10.1093/infdis/jir348 ^ 11.0 11.1 Choi MJ, Cossaboom CM, Whitesell AN, Dyal JW, Joyce A, Morgan RL, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 (PDF) . MMWR Recommendations and Reports. January 2021, 70 (1): 1–12 [2022-11-06 ] . PMC 7802368 PMID 33417593 doi:10.15585/mmwr.rr7001a1 存檔 (PDF) 於2021-03-20）. ^ Grady, Denise. Ebola Vaccine, Ready for Test, Sat on the Shelf . The New York Times . October 23, 2014 [December 21, 2019] . （原始內容存檔 於2020-06-14）. ^ Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine . July 2005, 11 (7): 786–90. PMID 15937495 S2CID 5450135 doi:10.1038/nm1258 ^ Merck & Co. Licenses NewLink's Ebola Vaccine Candidate . Genetic Engineering & Biotechnology News. November 24, 2014 [January 20, 2016] . （原始內容 存檔於May 18, 2018）. ^ First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response . U.S. Food and Drug Administration (FDA) (新聞稿). December 19, 2019 [December 19, 2019] . （原始內容存檔 於December 20, 2019）. ^ Ervebo . U.S. Food and Drug Administration (FDA). December 19, 2019 [March 28, 2020] . STN: 125690. （原始內容存檔 於2020-04-29）. ^ McKenzie, David. Fear and failure: How Ebola sparked a global health revolution . CNN . May 26, 2018 [May 26, 2018] . （原始內容存檔 於2019-08-26）.
公司董事 產品 出版物 其他相關公司：
默克集團 （從同一家德國公司分拆的兩個獨立公司） ·
先靈葆雅 （2009年被收購成為子公司）
. PMID 31384731. doi:10.1016/j.jvacx.2019.100009 
